Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Businessweek Archives

Now, `Gunsights' For Gene Therapy's Magic Bullets

Developments to Watch


IN THE FIVE YEARS SINCE DOCTORS BEGAN testing gene therapy, the results have been disappointing. It's easy enough to arm cells with a therapeutic gene and inject them into patients so that the doctored cells will secrete a beneficial product--say, a certain enzyme--into the bloodstream. But it's hard to get sufficient quantities of the enzyme to the sites where it's needed. To date, there have been no cases where gene therapy has definitively saved lives.

Inder Verma, co-director of the Salk Institute's Laboratory of Genetics in La Jolla, Calif., says there may be a better delivery system. Described in the August Proceedings of the National Academy of Science, it combines a harmless mouse virus with an antibody that will bind only to receptors in liver cells. Give the virus an altered gene, expose it to liver cells in vitro, and it binds to the correct receptor and passes along the gene.

In principle, such an approach could deliver a variety of medications, including clotting factor for hemophiliacs. And by pairing the virus with different antibodies, Verma believes he can target any organ in the body. Human tests could be three to five years away.EDITED BY OTIS PORT

blog comments powered by Disqus